SCHEMBL2257897

SCHEMBL2257897

O=C(C=Cc1ccc2cccc(O)c2c1)Nc1cc(-c2ccc(F)cc2)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM2 O94759 5/20 0.57
▸ TRPA1 O75762 3/20 0.54
▸ LTB4R Q15722 1/20 0.49
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ BCL2L1 Q07817 1/20 0.44
▸ BAD Q92934 1/20 0.44
▸ MMP1 P03956 6/20 0.44
▸ MMP2 P08253 6/20 0.44
▸ MMP9 P14780 6/20 0.44
▸ CYP1B1 Q16678 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HIF1A Q16665 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257892 1.00 TRPM2 (0.57) TRPM2TRPA1LTB4RMAOAMAOB
SCHEMBL2255104 0.81 BCL2L1 (0.67) BCL2L1BADCYP1B1MEN1KMT2A
SCHEMBL2255098 0.81 BCL2L1 (0.67) BCL2L1BADCYP1B1MEN1KMT2A
SCHEMBL2257660 0.81 ACLY (0.49) MEN1KMT2AHSD17B10PKM
SCHEMBL2255077 0.78 ACLY (0.52) MEN1ALDH1A1HPGDKMT2AKDM4E
SCHEMBL2256138 0.77 HCAR2 (0.59) —
SCHEMBL2253800 0.76 ACLY (0.50) BCL2L1BADALDH1A1HPGDHSD17B10
SCHEMBL2274109 0.75 TRPM2 (0.76) TRPM2TRPA1LTB4RMMP1MMP2
SCHEMBL2274104 0.75 TRPM2 (0.76) TRPM2TRPA1LTB4RMMP1MMP2
SCHEMBL2269338 0.75 TRPM2 (0.75) TRPM2TRPA1LTB4RMMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 — — US claimed
EP-1904047-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2013-01-02 — — EP disclosed
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 — — US disclosed
US-20100234456-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2010-09-16 — — US disclosed
US-7750004-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-06 — — US disclosed
US-20070135392-A1 Apoptosis promoters ABBVIE INC. 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234456-A1 APOPTOSIS PROMOTERS MCL1, BAX, BCL2 TRPM2 4308/4885TRPA1 4860/4885LTB4R 3731/4885
US-20070135392-A1 Apoptosis promoters MCL1, BAX, BCL2 TRPM2 4308/4885TRPA1 4860/4885LTB4R 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback